ClinicalTrials.gg
TerminatedNCT05171075MAGNOLIAUpdated Apr 17, 2026

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

A Phase 3 interventional study of Abelacimab and Dalteparin in Venous Thromboembolism, Deep Venous Thrombosis and Pulmonary Embolism, sponsored by Anthos Therapeutics, Inc.. Terminated at 117 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Anthos Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
417
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 107 studies in Venous Thromboembolism with a site in France — 23 open to participants now, 24 under way, 5 of them phase 3. Venous Thromboembolism · France.

Enrollment
37th of 62
417 · median 633
Started
2022
with 4 others
Phase 3
34 of 107
5 open now
Registered
85th of 107
by date

Among the 107 studies in Venous Thromboembolism with a site in France, this one is the 37th largest by enrollment of the 62 interventional ones that give a count, is one of 5 that started in 2022, is one of 34 in phase 3, and was the 85th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

23 of the 107 studies in Venous Thromboembolism with a site in France are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Venous Thromboembolism with a site in France, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Read the detailed description

Cancer associated thrombosis (CAT) is a severe medical condition which is characterized by high incidence of Venous thromboembolism (VTE) recurrence and high risk for bleeding. Patients with intact GI and GU cancer have increased bleeding risk with oral direct anticoagulants (DOACs), Guidelines advice caution with those DOACs or state preference for low molecular weight heparin (LMWH) in this population. The ANT-008 study will compare treatment with abelacimab monthly administration to LMWH daily subcutaneous (sc) administration over 6-month treatment. The study outcomes include VTE recurrence, bleeding event and treatment discontinuation at 6 months

03

Conditions studied

  • Venous Thromboembolism
  • Deep Venous Thrombosis
  • Pulmonary Embolism

Keywords

  • Anticoagulants
  • VTE recurrence rate
  • PROBE design
  • LMWH
  • CAT
  • Cancer associated VTE
  • GI cancer
  • Abelacimab
  • Dalteparin
  • GU cancer
  • FXI
  • Major bleeding events
  • CRNM bleeding events
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects ≥18 years old or other legal maturity age according to the country of residence
  • Confirmed GI (colorectal, pancreatic, gastric, esophageal, gastro-esophageal junction or hepatobiliary) or confirmed GU (renal, ureteral, bladder, prostate, or urethra) cancers if:

    • Unresectable, locally advanced, , or non-metastatic GI/GU cancer and
    • No intended curative surgery during the study
  • Confirmed symptomatic or incidental proximal lower limb deep vein thrombosis (DVT) (i.e., popliteal, femoral, iliac, and/or inferior vena cava vein thrombosis) and/or a confirmed symptomatic pulmonary embolism (PE), or an incidental PE in a segmental, or larger pulmonary artery. Patients are eligible within 120 hours from diagnosis of the qualifying VTE.
  • Anticoagulation therapy with LMWH for at least 6 months is indicated
  • Able to provide written

Exclusion criteria

Exclusion Criteria:

  • Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current (index) occurrence of DVT and/or PE
  • More than 120 hours of pre-treatment with therapeutic doses of UFH, LMWH, or other anticoagulants
  • An indication to continue treatment with therapeutic doses of an anticoagulant other than for VTE treatment prior to randomization (e.g., atrial fibrillation, mechanical heart valve, prior VTE)
  • PE leading to hemodynamic instability (systolic BP \<90 mmHg or shock).
  • Acute ischemic or hemorrhagic stroke or intracranial hemorrhage, in the last 4 weeks preceding screening.
  • Brain trauma, or cerebral or a spinal cord surgery or spinal procedures such as lumbar puncture or epidural/spinal anesthesia within 4 weeks of screening
  • Need for aspirin in a dosage of more than 100 mg/day or, any other antiplatelet agent alone or in combination with aspirin
  • Bleeding requiring medical attention at the time of randomization or in the preceding 4 weeks
  • Planned brain, spinal cord, cardiac, vascular, major thoracic and/or major abdominal surgery in the 4 weeks following randomization
  • History of heparin induced thrombocytopenia
  • Infective acute or subacute endocarditis at the time of presentation
  • Primary brain cancer or untreated intracranial
  • (ECOG) performance status of 3 or 4 at screening
  • of \<3 months at randomization
  • Calculated (CrCl) \<30 mL/min at the screening visit
  • count \<50,000/ mm3 at the screening visit
  • \<8 g/dL at the screening visit
  • Acute hepatitis, chronic active hepatitis, liver cirrhosis; or an ≥3 times and/or ≥2 times the (ULN) at the screening visit in the absence of clinical explanation
  • Uncontrolled hypertension (systolic blood pressure [BP] > 180 mm Hg or diastolic BP >100 mm Hg despite antihypertensive treatment)
  • Women of (WOCBP) who are unwilling or unable to use highly effective measures during the study from screening up to 3 days after last treatment of dalteparin or 100 days after administration of abelacimab
  • Sexually active males with sexual partners of childbearing potential must agree to use a condom or other reliable contraceptive measure up to 3 days after last treatment of dalteparin or 100 days after administration of abelacimab
  • Pregnant or breast-feeding women
  • History of to any of the study drugs (including dalteparin) or its , to drugs of similar chemical classes, or any listed in the label for dalteparin
  • Subjects with any condition that in the judgement of the Investigator would place the subject at increased risk of harm if he/she participated in the study
  • Use of other (not-registered) drugs within 5 half-lives prior to enrollment or until the expected pharmacodynamic effect has returned to baseline, whichever is longer. Participation in academic non-interventional studies or interventional studies, comprising testing different strategies or different combinations of registered drugs is permitted.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
417 participants (actual)

Study arms

  • Experimental
    Abelacimab

    Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously

    Biological: Abelacimab

  • Active comparator
    Dalteparin

    Dalteparin administered subcutaneously daily

    Drug: Dalteparin

Interventions

  • BiologicalAbelacimab

    Abelacimab 150 mg

    Also known as: MAA868

  • Dalteparin 200 IU/kg/day followed by 150 IU/kg/day

    Also known as: Fragmin

06

What researchers measure

Primary outcomes

  1. Time to first event of centrally adjudicated VTE recurrence

    Time to first adjudicated venous thromboembolism (VTE) event recurrence

    Time frame: up to 6 months

Secondary outcomes

  1. Time to first event of ISTH-adjudicated major or clinically relevant non-major (CRNM) bleeding events

    Time to first adjudicated major or clinically relevant non-major (CRNM) bleeding event

    Time frame: up to 6 months

  2. Time to first event of VTE recurrence, ISTH adjudicated major or ISTH-adjudicated CRNM bleeding events

    Time to first adjudicated venous thromboembolism (VTE) or bleeding event

    Time frame: up to 6 months

  3. Time to event of permanent treatment discontinuation not due to death

    Time to permanent discontinuation not due to death

    Time frame: up to 6 months

  4. Time to first event of ISTH-adjudicated CRNM bleeding events

    Time to first adjudicated clinically relevant non-major (CRNM) bleeding event

    Time frame: up to 6 months

  5. Time to first event of ISTH-adjudicated major bleeding events

    Time to first adjudicated major bleeding event

    Time frame: Up to 6 months

  6. Time to first event of GI ISTH-adjudicated major and GI CRNM bleeding events

    Time to first adjudicated gastrointestinal (GI) major and clinically relevant non-major (CRNM) bleeding event

    Time frame: up to 6 months

  7. All-cause death, vascular death, serious adverse events, adverse events leading to drug discontinuation, other adverse events, abnormal lab tests, etc. presented as rate per 100 patient-years

    Time frame: up to 6 months

  8. For patients treated with abelacimab: percent with injection site reactions/severity, hypersensitivity reactions/severity, anti-drug antibody formation, neutralizing antibody

    Time frame: up to 6 months

07

Study locations

117 sites
  • Washington DC VAMC
    Washington D.C., District of Columbia 20422, United States
  • NorthShore University Health System
    Evanston, Illinois 60201, United States
  • Barnes-Jewish Hospital
    St Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center-Middletown
    Middletown, New Jersey 07748, United States
  • Memorial Sloan Kettering Cancer Center-Commack
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Cancer Center-West Harrison
    Harrison, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021-0005, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Blacktown Hospital
    Blacktown, New South Wales 2148, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Northern Health
    Epping, Victoria 3076, Australia
  • LK Wiener Neustadt
    Neustadt, 2700, Austria
  • Medical University of Vienna
    Vienna, 1090, Austria
  • Hamilton Health Sciences, Juravinski Hospital and Cancer Centre
    Hamilton, Ontario L8V 1C3, Canada
  • Ottawa Hospital Research Instituite
    Ottawa, Ontario K1H 8L6, Canada
  • Ottawa Hospital Research Instituite
    Ottawa, Ontario K1H BL6, Canada
  • University of Calgary
    Calgary, T2N1N4, Canada
  • Sault Area Hospital
    Marie, P6A0A8, Canada
  • Toronto General Hospital
    Toronto, M5G 2C4, Canada
  • Beijing Shijitan Hosp.
    Beijing, 100038, China
  • Peking University Third Hospital
    Beijing, 100191, China
  • Jilin Province Tumor Hospital
    Ch’ang-ch’un, 130012, China
  • Southern Medical University - Zhujiang Hospital
    Guangdong, 510280, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, 510515, China
  • The Sixth Affiliated Hospital of Sun Yat-Sen University
    Guangzhou, 510655, China
  • Huizhou Municipal Central Hospital
    Huizhou, 516001, China
  • Nanjing First Hospital
    Nanjing, 210006, China
  • Nantong Tumor Hospital (Tumor Hospital Affiliated to Nantong University )
    Tongzhou, 226361, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, 325000, China
  • Union Hospital Tongji Medical College Huazhong University of Science &Technology
    Wuhan, 430023, China
  • Hubei Cancer Hospital
    Wuhan, 430079, China
  • The Second Hospital of Jiaxing
    Zhejiang, 314000, China
  • Masarykuv onkologicky ustav
    Brno, 65653, Czechia
  • University Hospital Hradec Kralove
    Hradec Králové, 50005, Czechia
  • Onkologická klinika VFN a 1. LF UK
    Prague, 128 08, Czechia
  • Thomayerova nemocnice
    Prague, 14059, Czechia
  • CHU de Limoges - Hôpital Dupuytren
    Limoges, Cedex 87042, France
  • CH Le Puy en Velay
    Le Puy-en-Velay, Chantemesse 43 000, France
  • Hôpital Louis Mourier
    Colombes, Renouiflers 92700, France
  • CHU de Nancy - Hôpital de Brabois Adultes
    Vandœuvre-lès-Nancy, Rue Du Morvan 54500, France
  • Nouvel Hôpital Civil de Strasbourg
    Strasbourg, Strasbourg 67091, France
  • CHU Angers - Hôpital Hôtel Dieu
    Angers, 49933, France
  • CHU Clermont Ferrand - Hopital Gabriel Montpied
    Clermont-Ferrand, 63003, France
  • CHU de Limoges - Hôpital Dupuytren
    Limoges, 87042, France
  • Groupe Hospitalier Pitie-Salpetriere
    Paris, 75013, France
  • Hôpital Européen Georges Pompidou
    Paris, 75015, France
  • Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud
    Pierre-Bénite, 69310, France
  • CHU de Rouen - Hôpital de Bois Guillaume
    Rouen, 76031, France
  • CHU de Saint-Etienne - Hopital Nord
    Saint-Etienne, 42000, France
  • CHU Strasbourg - Nouvel Hôpital Civil
    Strasbourg, 67091, France
  • Centre Hospitalier Intercommunal de Toulon
    Toulon, 83000, France
  • CHU de Nancy - Hôpital de Brabois Adultes
    Vandœuvre-lès-Nancy, 54511, France
  • Staedtisches Klinikum Dresden Standort Dresden-Friedrichstadt
    Dresden, 01067, Germany
  • Universitaetsklinikum Carl Gustav Carus TU Dresden
    Dresden, 1307, Germany
  • Praxis für Gefäßmedizin
    Görlitz, 2827, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universitätsklinik Leipzig
    Leipzig, 4103, Germany
  • Debreceni Egyetem
    Debrecen, 4032, Hungary
  • Markhot Ferenc Oktatokorhaz es Rendelointezet
    Eger, H-3300, Hungary
  • Cork University Hospital
    Cork, T12 DC4A, Ireland
  • Bon Secour Hospital
    Cork, T12 DV56, Ireland
  • Beaumont Hospital
    Dublin, D09V2N0, Ireland
  • IRCCS Istituto Tumori Giovanni Paolo II
    Bari, 70124, Italy
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia
    Bologna, 40133, Italy
  • Presidio Ospedaliero di Castelfranco Veneto
    Castelfranco Veneto, 31033, Italy
  • SS. ma Annunziata
    Chieti, 66013, Italy
  • Ospedale Civile Dell Annunziata
    Cosenza, 87100, Italy
  • Ospedale Degli Infermi
    Faenza, 48018, Italy
  • Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo
    Milan, 20142, Italy
  • Istituto Nazionale Tumori Fondazione G. Pascale
    Naples, 80131, Italy
  • Azienda Ospedale - Università Padova
    Padova, 35128, Italy
  • Ospedale Universitario
    Padova, 35128, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, 56126, Italy
  • Ospedale San Bortolo di Vicenza
    Vicenza, 36100, Italy
  • Daugavpils Regional Hospital
    Daugavpils, LV-5417, Latvia
  • Liepaja Regional Hospital
    Liepāja, LV3414, Latvia
  • Pauls Stradins CUH
    Riga, LV-1002, Latvia
  • Meander Medisch Centrum
    Amersfoort, 3813, Netherlands
  • Albert Schweitzer Ziekenhuis, Dordwijk
    Dordrecht, 3317 NM, Netherlands
  • Spaarne Gasthuis (Kennemer Gasthuis) - Haarlem-Zuid
    Haarlem, Netherlands
  • Amsterdam University Medical Center
    Holland, 1105AZ, Netherlands
  • Leids Universitair Medisch Centrum
    Leiden, 2333 ZA, Netherlands
  • Radboud Universitair Medisch Centrum
    Nijmegen, 6500, Netherlands
  • Ikazia Ziekenhuis
    Rotterdam, 3083 AN, Netherlands
  • Haga Ziekenhuis
    The Hague, 2545 AA, Netherlands
  • Østfold Hospital Kalnes
    Fredrikstad, 1603, Norway
  • Akershus Univeristy Hospital
    Lørenskog, 1478, Norway
  • Jeonbuk National University Hospital
    Jeonju, 54907, South Korea
  • Seoul National University Bundang Hospital
    Seongnam, 13620, South Korea
  • Ewha Womans University Mokdong Hospital
    Seoul, 7985, South Korea
  • Hospital Universitario Del Vinalopo
    Alicante, 03293, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
  • Hospital General Universitario de Elche
    Elche, 3203, Spain
  • Hospital Universitario Virgen de las Nieves
    Granada, 18014, Spain
  • Hospital Universitario Ciudad de Jaen
    Jaén, 23007, Spain
  • Hospital Universitario Lucus Augusti
    Lugo, 27003, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain

Showing the first 100 of 117 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Apr 2026, 42 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2021
First posted
Dec 28, 2021
StartActual
Sep 27, 2022
Primary completionActual
Apr 10, 2026
CompletionActual
Apr 10, 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05171075
Lead sponsor
Anthos Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 28, 2021
Start date
Sep 27, 2022
Primary completion
Apr 10, 2026
Completion
Apr 10, 2026
Last update
Apr 17, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abelacimab

Start the discussion